Published in Mol Carcinog on September 01, 1999
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev (2006) 5.53
Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation. Am J Pathol (2000) 2.63
Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol (2005) 2.41
Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol (2000) 1.81
Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci U S A (2000) 1.64
Molecular and functional consequences of Smad4 C-terminal missense mutations in colorectal tumour cells. Biochem J (2004) 1.05
BMP suppresses PTEN expression via RAS/ERK signaling. Cancer Biol Ther (2007) 0.99
On the role of transforming growth factor-beta in the growth inhibitory effects of retinoic acid in human pancreatic cancer cells. Mol Cancer (2007) 0.95
Restoration of Smad4 in BxPC3 pancreatic cancer cells attenuates proliferation without altering angiogenesis. Clin Exp Metastasis (2005) 0.91
Disruption of TGFbeta signaling pathways in human pancreatic cancer cells. Ann Surg (2000) 0.91
Ski promotes tumor growth through abrogation of transforming growth factor-beta signaling in pancreatic cancer. Ann Surg (2007) 0.90
Alterations in the Smad pathway in human cancers. Front Biosci (Landmark Ed) (2012) 0.89
The Notch ligand Delta-like 1 integrates inputs from TGFbeta/Activin and Wnt pathways. Exp Cell Res (2011) 0.88
Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defects. Am J Pathol (2001) 0.86
SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells. BMC Cancer (2014) 0.86
TGFbeta-mediated signaling and transcriptional regulation in pancreatic development and cancer. Curr Opin Gastroenterol (2001) 0.82
TGF-β signaling and its role in the regulation of hematopoietic stem cells. Syst Synth Biol (2015) 0.79
Personalized medicine in pancreatic cancer: prognosis and potential implications for therapy. J Gastrointest Surg (2012) 0.77
Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82
Definition of a consensus binding site for p53. Nat Genet (1992) 12.76
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (1996) 11.13
Gene expression profiles in normal and cancer cells. Science (1997) 9.65
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38
Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol (2001) 6.30
Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell (1998) 5.88
Allelotype of colorectal carcinomas. Science (1989) 5.54
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63
Progression model for pancreatic cancer. Clin Cancer Res (2000) 4.60
Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res (1997) 4.54
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res (2001) 4.19
Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet (1996) 4.09
Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res (2000) 3.74
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
Scrambled exons. Cell (1991) 3.65
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res (1996) 3.60
Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell (1991) 3.59
Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res (1995) 3.33
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res (1997) 3.17
The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res (2001) 3.02
Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res (1998) 2.89
p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res (1997) 2.88
p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res (1994) 2.80
The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo. Genes Dev (1998) 2.72
Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation. Am J Pathol (2000) 2.63
Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol (1999) 2.59
Genetic progression in the pancreatic ducts. Am J Pathol (2000) 2.58
Mad-related genes in the human. Nat Genet (1996) 2.51
Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res (2001) 2.50
Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res (1994) 2.26
Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res (1998) 2.23
Allelotype of pancreatic adenocarcinoma. Cancer Res (1994) 2.11
Microdissection and polymerase chain reaction amplification of genomic DNA from histological tissue sections. Am J Pathol (1997) 2.08
Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am (1998) 2.03
Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res (2001) 1.98
Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res (1998) 1.97
Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. Cancer Res (2001) 1.96
Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol (2000) 1.81
Colorectal neoplasia in juvenile polyposis or juvenile polyps. Arch Dis Child (1991) 1.81
Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling. Cancer Res (2001) 1.78
Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res (1996) 1.75
BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol (2000) 1.72
Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res (1998) 1.71
Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity. Am J Pathol (2000) 1.69
Remifentanil by bolus injection: a safety, pharmacokinetic, pharmacodynamic, and age effect investigation in human volunteers. Br J Anaesth (2004) 1.62
Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol (1996) 1.57
Molecular pathology of pancreatic cancer. Cancer J (2001) 1.56
Targeted deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells. Proc Natl Acad Sci U S A (1998) 1.55
A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res (2000) 1.53
Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers. Cancer Res (2001) 1.49
Direct demonstration in intestinal secretions of an IgA memory response to orally administered Shigella flexneri antigens. J Immunol (1982) 1.46
Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol (1998) 1.42
Wild-type, but not mutant, human p53 proteins inhibit the replication activities of simian virus 40 large tumor antigen. Proc Natl Acad Sci U S A (1990) 1.39
Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet (2004) 1.39
Upper and lower limb standards in newborn. Indian Pediatr (1989) 1.38
Identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiol Biomarkers Prev (1998) 1.36
C3 proactivator (C3PA) as an acute phase reactant. Clin Exp Immunol (1974) 1.35
K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol (1995) 1.35
Nomenclature: vertebrate mediators of TGFbeta family signals. Cell (1996) 1.34
Familial pancreatic cancer. Ann Oncol (1999) 1.33
Mechanoreceptors in the human anterior cruciate ligament. Anat Rec (1986) 1.32
Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res (1992) 1.31
Familial pancreatic cancer: a review. Semin Oncol (1996) 1.30
Dpc4 transcriptional activation and dysfunction in cancer cells. Cancer Res (1998) 1.29
ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc Natl Acad Sci U S A (2001) 1.29
Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. Gastroenterology (1995) 1.23
Progress in cancer genetics: lessons from pancreatic cancer. Ann Oncol (1999) 1.22
p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol (1995) 1.20
G1 cell cycle arrest and apoptosis induction by nuclear Smad4/Dpc4: phenotypes reversed by a tumorigenic mutation. Proc Natl Acad Sci U S A (1999) 1.19
Molecular genetic basis of pancreatic adenocarcinoma. Genes Chromosomes Cancer (1999) 1.19
Efficacy of local dipyridamole therapy in a porcine model of arteriovenous graft stenosis. Kidney Int (2006) 1.17
Tumor-suppressor genes in pancreatic cancer. J Hepatobiliary Pancreat Surg (1998) 1.17
Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma. Cancer Res (1996) 1.14
Role of Mdm4 in drug sensitivity of breast cancer cells. Oncogene (2010) 1.13
Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression. Am J Surg Pathol (2000) 1.13
Pathology of incipient pancreatic cancer. Ann Oncol (1999) 1.10